Low-dose paclitaxel elution by novel bioerodible sol-gel coating on stents inhibits neointima with low toxicity in porcine coronary arteries

International Journal of Cardiology

Volumn 135, Issue 1, 2009, Pages 93-101

  Shinke, Toshiro ^a   Geva, Sarah ^a   Pendyala, Lakshmana ^a   Jabara, Refat ^a   Li, Jinsheng ^a   Chen, Jack P ^a   Venegoni, Anna ^b   Colley, Kenneth ^b   Klein, Richard ^b   Chronos, Nicolas ^a   Robinson, Keith ^a   Hou, Dongming ^a  

^a Saint Joseph's Hospital of Atlanta   (United States)

^b Medlogics Device Corporation   (United States)

Author keywords

Bioerodible; Paclitaxel eluting stent; Polymer; Sol gel

Indexed keywords

PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTERY MEDIA; ARTERY THROMBOSIS; ARTICLE; BARE METAL STENT; BIODEGRADABLE IMPLANT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG ELUTING STENT; IN-STENT RESTENOSIS; INFLAMMATORY INFILTRATE; LOW DRUG DOSE; NONHUMAN; PHASE TRANSITION; PRIORITY JOURNAL; SLOW DRUG RELEASE; SWINE; VASCULAR NECROSIS;

ANIMALS; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-ELUTING STENTS; FEMALE; GELS; MALE; NECROSIS; PACLITAXEL; POLYMERS; SUS SCROFA; TUBULIN MODULATORS; TUNICA INTIMA;

EID: 67349113986     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2008.06.030     Document Type: Article

References (33)

1. Stettler C., Wandel S., Allemann S., et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370 (2007) 937-948
2. Stone G.W., Moses J.W., Ellis S.G., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008
3. Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2130
4. Pfisterer M., et al., BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48 (2006) 2584-2591
5. Kuchulakanti P.K., Chu W.W., Torguson R., et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 113 (2006) 1108-1113
6. Daemen J., Wenaweser P., Tsuchida K., et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369 (2007) 667-678
7. Joner M., Finn A.V., Farb A., et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48 (2006) 193-202
8. Finn A.V., Joner M., Nakazawa G., et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 115 (2007) 2435-2441
9. Finn A.V., Nakazawa G., Joner M., et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 27 (2007) 1500-1510
10. Mauri L., Hsieh W.H., Massaro J.M., Ho K.K., D'Agostino R., and Cutlip D.E. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356 (2007) 1020-1029
11. Windecker S., and Meier B. Late coronary stent thrombosis. Circulation 116 (2007) 1952-1965
12. Abal M., Andreu J.M., and Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets 3 (2003) 193-203
13. Kamath K.R., Barry J.J., and Miller K.M. The Taxus™ drug-eluting stent: a new paradigm in controlled drug delivery. Adv Drug Deliv Rev 58 (2006) 412-436
14. Halkin A., and Stone G.W. Polymer-based paclitaxel-eluting stents in percutaneous coronary intervention: a review of the TAXUS trials. J Interv Cardiol 17 (2004) 271-282
15. Virmani R., Farb A., Guagliumi G., and Kolodgie F.D. Drug-eluting stents: caution and concerns for long-term outcome. Coron Artery Dis 15 (2004) 313-318
16. Arayne M.S., and Sultana N. Porous nanoparticles in drug delivery systems. Pak J Pharm Sci 19 (2006) 158-169
17. Coradin T., Boissiere M., and Livage J. Sol-gel chemistry in medicinal science. Curr Med Chem 13 (2006) 99-108
18. Hong M.K., Kornowski R., Bramwell O., Ragheb A.O., and Leon M.B. Paclitaxel-coated Gianturco-Roubin II (GR II) stents reduce neointimal hyperplasia in a porcine coronary in-stent restenosis model. Coron Artery Dis 12 (2001) 513-515
19. Zhou X., Li J., and Kucik D.F. The microtubule cytoskeleton participates in control of beta2 integrin avidity. J Biol Chem 276 (2001) 44762-44769
20. Wessely R., Blaich B., BelAiba R.S., et al. Comparative characterization of cellular and molecular anti-restenotic profiles of paclitaxel and sirolimus: implication for local drug delivery. Thromb Haemost 97 (2007) 1003-1012
21. Axel D.I., Kunert W., Göggelmann C., et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 96 (1997) 636-645
22. Farb A., Heller P.F., Shroff S., et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 104 (2001) 473-479
23. Rogers C.D. Drug-eluting stents: clinical perspectives on drug and design differences. Rev Cardiovasc Med 6 (2005) S3-S12
24. Cutlip, Chauhan M., Baim D., et al. Clinical restenosis after coronary stenting perspectives from multicenter clinical trials. J Am Coll Cardiol 40 (2002) 2082-2089
25. Ellis S.G., Popma J.J., Lasala J.M., et al. Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation analysis from the TAXUS-IV trial. J Am Coll Cardiol 45 (2005) 1193-1200
26. Drachman D.E., Edelman E.R., Seifert P., et al. Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J Am Coll Cardiol 36 (2000) 2325-2332
27. Finkelstein A., McClean D., Kar S., et al. Local drug delivery via a coronary stent with programmable release pharmacokinetics. Circulation 107 (2003) 777-784
28. Heldman A.W., Cheng L., Jenkins G.M., et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 103 (2001) 2289-2295
29. Jabara R., Chronos N., Tondato F., et al. Toxic vessel reaction to an absorbable polymer-based paclitaxel-eluting stent in pig coronary arteries. J Invasive Cardiol 18 (2006) 383-390
30. Cook S., Wenaweser P., Togni M., et al. Incomplete stent apposition and very late stent thrombosis after drug-gluting stent implantation. Circulation 115 (2007) 2426-2434
31. Gershlick A., De Scheerder I., Chevalier B., et al. Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. Circulation 109 (2004) 487-493
32. Virmani R., Kolodgie F.D., Farb A., and Lafont A. Drug eluting stents: are human and animal studies comparable?. Heart 89 (2003) 133-138
33. Schwartz R.S., Edelman E.R., Carter A., et al. Preclinical evaluation of drug-eluting stents for peripheral applications: recommendations from an expert consensus group. Circulation 110 (2004) 2498-2505